Telomerase Expression as a Marker in Prostate Cancer: Correlation to Clinicopathologic Predictors

Journal of Experimental and Clinical Cancer Research

Volumn 22, Issue 4, 2003, Pages 613-618

  Athanassiadou, Pauline ^a,b   Bantis, A ^a   Gonidi, M ^a   Liossi, A ^a   Aggelonidou, E ^a   Petrakakou, E ^a   Giannopoulos, A ^a  

^a Athens University and Urology Clinic   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

In situ hybridization; Prognostic factors; Prostate cancer; Telomerase

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TELOMERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SMEAR;

ADENOCARCINOMA; AGED; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; LINEAR MODELS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 1242269703     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kim N.W., Piatyszek M.A., and Prowse K.R., et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
2. Suenaga M., Soda H., Oka M. et al: Histone deacitilase inhibitors suppres telomerase reverse transcriptase mRNA expression in prostate cancer cells. Int. J. Cancer 5:621-625, 2002.
3. Shay J., and Wright W.: Telomerase activity in human cancer. Curr. Opin. Oncol. 8: 66-71, 1996.
4. Yoshida K., Sugino T., and Goodison S., et al: Detection of telomerase activity in exfoliated cancer cells in colonic luminal washings and its related clinical implications. Br. J. Cancer 75:548-553, 1997.
5. Niiyama H., Mizumoto K., and Kusumoto M., et al: Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms. Cancer 85:2138-2143, 1999.
6. Nouso K., Urabe Y., and Higashi T., et al: Telomerase as a tool for the differential diagnosis of human hepatocellular carcinoma. Cancer 78: 232-236, 1996.
7. Lin Y., Uemura H., and Fujinami K., et al: Telomerase activity in primary prostate cancer. J. Urol. 157: 1161-1165, 1997.
8. Meid F., Gygi Ch., and Leisinger H.J., et al: The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. J. Urol. 165: 1802-1805, 2001.
9. Fleming I., Cooper J., and Henson D.E., et al.: American Joint Committee on Cancer. Cancer Staging Handbook, 5th Ed. Lippincott Williams & Wilkins, Philadelphia, pp 203-208, 1998.
10. Zhang W., Kapusta L.R., and Slingerlaud J.M., et al: Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic epithelium. Cancer Res. 58: 619-621, 1998.
11. Orlando C., Gelmini S., Selli C., and Pazzagli M.: Telomerase in urological malignancy. J. Urol. 166: 666-673, 2001.
12. Wymenga L.F., Wisman G.B., and Veenstra R., et al: Telomerase activity in needle biopsies from prostate cancer and benign prostates. Eur. J. Clin. Invest. 30: 330-335, 2000.
13. Scates D.K., Muir G.H., Venitt S., and Carmichael P.: Detection of telomerase activity in human prostate: a diagnostic marker for prognostic cancer? Br. J. Urol. 80: 263-268, 1997.
14. Engelhardt M., Albanell J., and Drallinsky P., et al: Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon and sarcoma. Clin. Cancer Res. 3: 1849-1856, 1997.
15. Wullich B., Rohde V., and Oehlenschlager B., et al: Focal intratumoral heterogeneity for telomerase activity in human prostate cancer. J. Urol. 161: 1997-2001, 1999.
16. Abrahamsson P.A., Lilja H., and Oesterling J.: Molecular forms of serum prostate specific antigen: The clinical value of percent free prostate specific antigen. Urol. Clin. North. Am. 24: 353-364, 1997.
17. Partin A., and Oesterling J.: The clinical usefulness of prostate specific antigen: update 1994. J. Urol. 152: 1358-1368, 1994.
18. Kleer E., and Oesterling J.: PSA and staging of localized prostate cancer. Urol. Clin. N. Amer. 20: 695-704, 1993.
19. Carter H.B., and Pearson J.D.: Prostate specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines. Urology 54: 780-786, 1999.
20. Slovin S.F., and Scher H.I.: Rising PSAs after primary therapy active or passive intervention. Semin. Urol. Oncol. 17: 164-173, 1999.
21. Sommerfeld H.J., Meeker A.K., and Piatyszek M.A., et al: Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res. 56: 218-222, 1996.
22. Wymenga L., Wisman G., and Veenstra R., et al: Telomerase activity in needle biopsies from prostate cancer and benign prostates. Eur. J. Clin. Invest. 30: 330-335, 2000.